Salvinorin A (SalvA), a compound from the plant Salvia divinorum that activates κ-opioid receptors, may have antidepressant effects. In a study using male and female Long-Evans rats, chronic mild stress (CMS) for three weeks reduced their preference for sucrose water, indicating anhedonia, a key symptom of depression. After three more weeks of CMS, rats given daily injections of 1 mg SalvA per kilogram of body weight showed a reversal of this anhedonia, while control rats did not. Nonstressed rats given the same dose showed no change in sucrose preference. The findings suggest that chronic SalvA treatment acts as an effective antidepressant in this animal model.
Opioids, long known for pain and addiction, are now recognized as central to mood regulation, potentially shifting focus from monoamine neurotransmitters to opioid systems in depression. Dynorphin, the last major endogenous opioid discovered, and its kappa receptor have distinct, often opposite effects from mu-receptor opioids like beta-endorphin and morphine. This review examines dynorphin/kappa neurobiology in relation to major depressive disorder (MDD). Salvinorin A, a plant-based kappa agonist, shows a complex pharmacological profile beyond kappa agonism, making it a promising candidate for MDD treatment research.